Singapore March 6, 2008. bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, announced today the opening of a subsidiary and regional office in Singapore. Based in BioPolis, the new subsidiary will provide support to all of Asia Pacific Commercial Operations. bioMérieux's 38th subsidiary is another milestone in the company's international expansion. This additional location highlights the strategic importance of Asia for bioMérieux. The company's diagnostics solutions have been sold in Singapore for over 25 years by a local distributor with the support of a BioMerieux Global team located throughout Asia and France. The management team now located in Singapore will allow bioMerieux direct access to their clients and the proximity to establish collaborations with the vibrant and large BioTech industry located in Singapore, stated Ms. Darshna Tanna, bioMérieux ,VP Asia Pacific Commercial Operations. "During my first visit to Singapore, it confirms the potential for bioMerieux to partner with Singapore's BioTech and Pharmaceutical companies to enhance our product offerings and for further collaboration on the development of new products and technologies, " stated Mr Alexandre Merieux, bioMérieux Corporate Vice President. bioMérieux's meeting today with Economic Develoment Bank and A*Star reinforces its strong commitment to develop in Singapore a presence through partnerships with local research centers, Pharma and BioTech enterprises. The company will extend its activities by investing in skills development programs for health workers, laboratory technicians and biologists. As a worldwide leader in microbiology testing techniques in protecting patients from healthcare-associated infections will also be an area of focus for bioMérieux. "We are very pleased that bioMerieux, a global leader for in vitro diagnostics, is setting up its Asia-Pacific headquarters in Singapore," said Mr Yeoh Keat Chuan, Executive Director, Biomedical Sciences, Singapore Economic Development Board. "Singapore's conducive business environment, world class financial and logistics infrastructure, and ability to attract global talents enable companies based here to access the rapidly growing Asian market." About bioMérieux Advancing Diagnostics to Improve Public Health A world leader in the field of in vitro diagnostics for 45 years, bioMérieux is present in more than 150 countries through 37 subsidiaries and a large network of distributors. In 2007, revenues reached €1.063 billion with 84% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on Euronext Paris. Other information can be found at http://www.biomerieux.com/. bioMérieux Contact: bioMérieux Koren Wolman-Tardy Tél : + 33 4 78 87 20 08 media@eu.biomerieux.com